We therefore suggest our results warrant further validation in larger patient cohorts to better determine how the measurement of circulating Fat1 can be applied as a new biomarker to benefit pancreatic cancer patients, either complementary to CA19-9, or substituting for CA19-9 in monitoring pancreatic patients with the Lewis Lung-negative phenotype. The gene discussed is FAT1; the disease is pancreatic neoplasm.